Get started
Heron Therapeutics, Inc.Heron Therapeutics, Inc.Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

HRTX chart


Full chart

HRTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪280.29 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.09 USD
Net income (FY)
‪−13.58 M‬ USD
Revenue (FY)
‪144.28 M‬ USD
Shares float
‪150.94 M‬
Beta (1Y)
0.75

Employees


Employees (FY)
122
Change (1Y)
−4 −3.17%
Revenue / Employee (1Y)
‪1.18 M‬ USD
Net income / Employee (1Y)
‪−111.31 K‬ USD

About Heron Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Craig A. Collard
Website
herontx.com
Headquarters
Cary
Founded
1983
FIGI
BBG000G2GJT7
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HRTX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as HRTX.

Frequently Asked Questions


The current price of HRTX is 1.84 USD — it hasn't changed in the past 24 hours. Watch Heron Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Heron Therapeutics, Inc. stocks are traded under the ticker HRTX.
HRTX stock has risen by 1.66% compared to the previous week, the month change is a −21.70% fall, over the last year Heron Therapeutics, Inc. has showed a −37.63% decrease.
We've gathered analysts' opinions on Heron Therapeutics, Inc. future price: according to them, HRTX price has a max estimate of 9.00 USD and a min estimate of 4.00 USD. Watch HRTX chart and read a more detailed Heron Therapeutics, Inc. stock forecast: see what analysts think of Heron Therapeutics, Inc. and suggest that you do with its stocks.
HRTX reached its all-time high on Jan 13, 1992 with the price of 1,290.00 USD, and its all-time low was 0.50 USD and was reached on Nov 9, 2023. View more price dynamics on HRTX chart.
See other stocks reaching their highest and lowest prices.
HRTX stock is 3.86% volatile and has beta coefficient of 0.75. Track Heron Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Heron Therapeutics, Inc. there?
Today Heron Therapeutics, Inc. has the market capitalization of ‪280.29 M‬, it has increased by 2.13% over the last week.
Yes, you can track Heron Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Heron Therapeutics, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
HRTX earnings for the last quarter are 0.02 USD per share, whereas the estimation was −0.031 USD resulting in a 165.47% surprise. The estimated earnings for the next quarter are −0.0097 USD per share. See more details about Heron Therapeutics, Inc. earnings.
Heron Therapeutics, Inc. revenue for the last quarter amounts to ‪40.78 M‬ USD, despite the estimated figure of ‪37.29 M‬ USD. In the next quarter, revenue is expected to reach ‪37.52 M‬ USD.
HRTX net income for the last quarter is ‪3.66 M‬ USD, while the quarter before that showed ‪−4.85 M‬ USD of net income which accounts for 175.56% change. Track more Heron Therapeutics, Inc. financial stats to get the full picture.
No, HRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 122 employees. See our rating of the largest employees — is Heron Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Heron Therapeutics, Inc. EBITDA is ‪−9.04 M‬ USD, and current EBITDA margin is −6.26%. See more stats in Heron Therapeutics, Inc. financial statements.
Like other stocks, HRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Heron Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Heron Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Heron Therapeutics, Inc. stock shows the strong sell signal. See more of Heron Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.